Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Biobobon Apr 06, 2022 10:05am
105 Views
Post# 34580152

RE:RE:RE:RE:SBFM up 150% on mRNA oncology news

RE:RE:RE:RE:SBFM up 150% on mRNA oncology news The problem we have as Th shareholders is that when disturbing events like this one occurs out of the blue it should be viewed as an opportunity by some market players like Soleus.  Because of their communication and self esteem problems we are sitting ducks between now and some game changer events.  They actually beleive Thera is a 3$ company since they were willing to do a financing at that price.  Now I'm shure they will confirm that view once again with a similar deal because of the market conditions of course.  I'm voting not to send a message but for a change this year.  I hope many shareholders decide like me to take the future of their investment in hand and actually do something about it.  If it does'nt work out for change you gain the right to complain.  If you don't vote you don't get to complain, you accept the statu quo.  Now what are the alternatives, that is an interesting debate to start.
<< Previous
Bullboard Posts
Next >>